Lily Yang MD/PhD
- Department of Surgery
Professor
- (404) 778-4269
- lyang02@emory.edu
- Lily Yang
-
Emory University
Surgery
Clininc C, Room C-4088
Overview
Dr. Yang holds multiple NIH grants and is a translational cancer researcher who specializes in the development of novel cancer imaging and targeted therapeutic agents. Her research experiences include tumor immunology, cancer stem cells, cancer gene therapy, apoptosis resistance, molecular targeted cancer therapy, nanoparticle imaging probes, and theranostic nanoparticles for targeted cancer therapy and imaging. Dr. Yang is a member of the Cancer Cell Biology Research Program at Winship Cancer Institute of Emory University, and holds professional memberships with American Association for Cancer Research, American Society of Nanomedicine, and National Cancer Institute Alliance for Nanotechnology in Cancer.
Her research projects focus on the development of novel cancer nanotechnologies and imaging methods to address the major challenges in clinical oncology of early cancer detection, targeted drug delivery, overcoming drug resistance, assessment of therapeutic response using non-invasive imaging, and image-guided surgery.
Academic Appointment
- Professor with Tenure, Department of Surgery, Emory University School of Medicine
- Nancy Panoz Chair of Surgery in Cancer Research, Surgery, Emory University
- Associate Professor, Department of Radiology and Imaging Sciences, Emory University School of Medicine
Education
Degrees
- PhD from Brown University
- Master of Medicine from Institute of Epidemiology & Microbiology, Chinese Academy of Preventive Medicine
- MD from West China University of Medical Sciences
Research
Focus
- 1).Development of multifunctional nanoparticles for targeted and image-guided cancer therapy; 2).Novel targeted MR imaging probes for cancer detection; 3).Tumor targeted optical imaging probes for image-guided surgery; 4).Signal pathways and molecular mechanisms that confer aggressive behavior and drug resistance of breast cancer cells (e.g. breast cancer stem cells).
Publications
-
Dual inhibition of oxidative phosphorylation and glycolysis using a hyaluronic acid nanoparticle NOX inhibitor enhanced response to radiotherapy in colorectal cancer.
Biomaterials Volume: 323 Page(s): 123437
12/01/2025 Authors: Zhang L; Liu T; Chen M; Gao S; Staley CA; Yang L; Zhu L -
Muc16CD is a novel CAR Tcell target antigen for the treatment of pancreatic cancer.
Mol Ther Oncol Volume: 32 Page(s): 200868
12/19/2024 Authors: Lin HK; Blake DA; Liu T; Freeman R; Lesinski GB; Yang L; Rafiq S -
Shape-dependent cellular uptake of iron oxide nanorods: mechanisms of endocytosis and implications on cell labeling and cellular delivery.
Nanoscale Volume: 16 Page(s): 21398 - 21415
11/28/2024 Authors: Thamizhchelvan AM; Ma H; Wu T; Nguyen D; Padelford J; Whitworth TJ; Li Y; Yang L; Mao H -
Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy.
Nanoscale Volume: 16 Page(s): 17699 - 17722
10/03/2024 Authors: Wells K; Liu T; Zhu L; Yang L -
The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy.
Front Immunol Volume: 14 Page(s): 1154566
01/01/2023 Authors: Zhang H; Passang T; Ravindranathan S; Bommireddy R; Jajja MR; Yang L; Selvaraj P; Paulos CM; Waller EK -
Non-invasive detection and complementary diagnosis of liver metastases via chemokine receptor 4 imaging.
Cancer Gene Ther Volume: 29 Page(s): 1827 - 1839
12/01/2022 Authors: Yang H; Tan S; Qiao J; Xu Y; Gui Z; Meng Y; Dong B; Peng G; Ibhagui OY; Qian W -
Inhibition of NADPH Oxidase-ROS Signal using Hyaluronic Acid Nanoparticles for Overcoming Radioresistance in Cancer Therapy.
ACS Nano Volume: 16 Page(s): 18708 - 18728
11/22/2022 Authors: Zhu L; Zhao Y; Liu T; Chen M; Qian WP; Jiang B; Barwick BG; Zhang L; Styblo TM; Li X -
Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma.
Wiley Interdiscip Rev Nanomed Nanobiotechnol Volume: 14 Page(s): e1793
07/01/2022 Authors: Zhu L; Mao H; Yang L -
Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer.
Nat Commun Volume: 12 Page(s): 1714
03/17/2021 Authors: Zhang B; Li Y; Wu Q; Xie L; Barwick B; Fu C; Li X; Wu D; Xia S; Chen J -
In Vivo Evaluation of a Miniaturized Fluorescence Molecular Tomography (FMT) Endoscope for Breast Cancer Detection Using Targeted Nanoprobes.
Int J Mol Sci Volume: 21
12/09/2020 Authors: Yang H; Qian W; Yang L; Xie H; Jiang H